Calcium-Activated Membrane Interaction Of The Islet Amyloid Polypeptide: Implications In The Pathogenesis Of Type Ii Diabetes Mellitus(962 views) Sciacca MFM, Pappalardo M, Milardi D, Grasso DM, La Rosa C
Dipartimento di Scienze Chimiche, Universita' di Catania, Viale Andrea Doria 6, 95125 Catania, Italy
Istituto CNR di Biostrutture, Bioimmagini-Sezione di Catania, Viale Andrea Doria 6, 95125 Catania, Italy
Disciplina de Endocrinologia, Hospital Das Cl nicas da Faculdade de Medicina da Universidade de S o Paulo (HC-FMUSP)
Grupo de Obesidade e S ndrome Metab lica, Servi o de Endocrinologia e Metabologia, Hospital Das Cl nicas da Faculdade de Medicina da Universidade de S o Paulo (HC-FMUSP)
Disciplina Endocrinol. e Metabologia, Faculdade Med. da Univ. de S. Paulo
Grupo Obesidade Doencas Metabolicas, Serv. de Endocrinol. e Metabologia, Hosp. das Clínicas da FMUSP
Serv. de Clin. Medica de Emergecia, Grupo Obesidade Doencas Metabolicas, Hosp. Clinicas Faculdade Med. U.
Clinica Medica de Emergencia, Hospital das Clínicas, Univ. de São Paulo (HC-FMUSP), Brazil
Hospital Brigadeiro, Soc. Bras. de Endocrinol. e Metabol., Brazil
R. Bonsucesso, 241, CEP 03305-000 São Paulo - SP, Brazil
References: Cooper, G. S. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., Reid, K. B. M., (1987) Proc. Natl. Acad. Sci. USA, 84, pp. 8628-963
Westermark, P., Wernsted, C., Wilander, E., Hayden, D. W., O'Brien, T. D., Johnson, K. H., (1987) Proc. Natl. Acad. Sci. USA, 84, pp. 3881-3885
Lukinius, A., Wilander, E., Westermark, G. T., Engstrom, U., Westermark, P., (1989) Diabetologia, 32, pp. 240-244
Betsholtz, C., Christmansson, L., Engstr m, U., Rorsman, F., Svensson, V., Johnson, K. H., Westermark, P., (1989) FEBS Lett., 251, pp. 261-264
Fineman, M., Weyer, C., Maggs, D. G., Strobel, S., Kolterman, O. G., (2002) Horm. Metab. Res., 34, pp. 504-508
Ludvik, B., Thomaseth, K., Nolan, J. J., Clodi, M., Prager, R., Pacini, G., (2003) Eur. J. Clin. Invest., 33, pp. 316-322
Uversky, V. N., Fink, A. L., (2004) Biochim. Biophys. Acta, 1698, pp. 131-153
Betsholtz, C., Svensson, V., Rorsman, F., Engstrom, U., Westermark, G. T., Wilander, E., Johnson, K., Westermark, P., (1989) Exp. Cell Res., 183, pp. 484-493
Padrick, S. B., Miranker, A. D., (2002) Biochemistry, 41, pp. 4694-4703
Moriarty, D. F., Raleigh, D. P., (1999) Biochemistry, 38, pp. 1811-1818
Westermark, P., Engstrom, U., Johnson, K. H., Westermark, G. T., Betsholtz, C., (1990) Proc. Natl. Acad. Sci. USA, 87, pp. 5036-5040
Janson, J., Ashley, R. H., Harrison, D., Mcintyre, S., Butler, P. C., (1999) Diabetes, 48, pp. 491-498
Mirzabekov, T. A., Lin, M., Kagan, B. L., (1996) J. Biol. Chem., 271, pp. 1988-1992
Anguiano, M., Richard, J. N., Lansbury Jr., P. T., (2002) Biochemistry, 41, pp. 11338-11343
Jayasinghe, S. A., Langen, R., (2005) Biochemistry, 44, pp. 12113-12119
Ohnishi, S., Ito, T., (1974) Biochemistry, 13, pp. 881-887
Tamamizu-Kato, S., Kosaraju, M. G., Kato, H., Raussen, V., Ruysschaert, J., Narayanaswami, V., (2006) Biochemistry, 45, pp. 10947-10956
Qian, G., Yong-ming, D., Zhi-tao, H., Zheng-xing, W., Tao, X., (2006) Acta Pharmacol. Clin., 27, pp. 933-938
Jackson, M. B., Chapman, E. R., (2006) Annu. Rev. Biophys. Biomol. Struct., 35, pp. 135-160
Resnick, L. M., (1992) Am. J. Med., 93, pp. 11S-20S
Barbagallo, M., Gupta, R. K., Resnick, L. M., (1996) Diabetes Care, 19, pp. 1393-1398
Barbagallo, M., Novo, S., Licata, G., Resnick, L. M., (1993) Int. Angiol., 12, pp. 365-370
Mittlerneher, S., Knoll, W., (1989) Biochem. Biophys. Res. Commun., 162, pp. 124-129
Raudino, A., Castelli, F., Gurrieri, S., (1990) J. Phys. Chem., 94, pp. 1526-1535
Nagle, J. F., (1980) Annu. Rev. Phys. Chem., 31, pp. 157-196
Flory, P. D., (1975) Science, 188, pp. 1268-1276
(1982) Biological Membranes, 4. , Chapman D. (Ed), Academic Press, New York p. 179
Grasso, D., Milardi, D., La Rosa, C., Rizzarelli1, E., (2001) New J. Chem., 25, pp. 1543-1548
MacDonald, R. C., MacDonald, R. I., Menco, B. P., Takeshita, K., Subarrao, N. K., Hu, L., (1991) Biochim. Biophys. Acta, 1061, pp. 297-303
Higham, C. E., Jaikaran, E. T., Fraser, P. E., Gross, M., Clark, A., (2000) FEBS Lett., 470, pp. 55-60
Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I., Glabe, C. G., (2005) J. Biol. Chem., 280, pp. 17294-17300
Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T. M., Milton, S. C., Hall, J. E., Glabe, C. G., (2004) J. Biol. Chem., 279, pp. 46363-46366
Quist, A., Doudevski, I., Lin, H., Azimova, R., Ng, D., Frangione, B., (2005) Proc. Natl. Acad. Sci. USA, 102, pp. 10427-10432
Porat, Y., Kolusheva, S., Jelinek, R., Gazit, E., (2003) Biochemistry, 42, pp. 10971-10977
Engel, M. F. M., Yigittop, H. A., Elgersma, R. C., Rijkers, D. T. S., Liskamp, R. M. J., de Kruijff, B., H ppener, J. W. M., Killian, J. A., (2006) J. Mol. Biol., 356, pp. 783-789
Kiselev, M. A., Gutberlet, T., Lesieur, P., Hauss, T., Ollivon, M., Neubert, R. H. H., (2005) Chem. Phys. Lipids, 133, pp. 181-193
Larson, J. L., Miranker, A. D., (2004) J. Mol. Biol., 335, pp. 221-231
Hirota, N., Mizuno, K., Goto, Y., (1998) J. Mol. Biol., 2755, pp. 365-378
Notman, R., Noro, M., O'Malley, B., Anwar, J., (2006) J. Am. Chem. Soc., 128, pp. 13982-13983
Kornakowska, B., Aitken, J. F., Kistler, J., Zhang, S., Cooper, G. J. S., (2006) FEBS J., 273, pp. 3614-3624
Knight, J. D., Miranker, A. D., (2004) J. Mol. Biol., 341, pp. 1175-1187
Arispe, N., Pollard, H. B., Rojas, E., (1993) Proc. Natl. Acad. Sci. USA, 90, pp. 10573-10577
Matsuzaki, K., Horikiri, C., (1999) Biochemistry, 38, pp. 4137-4142
Kremer, J. J., Pallitto, M. M., Sklansky, D. J., Murphy, R., (2000) Biochemistry, 39, pp. 10309-10318
Volles, M. J., Lee, S. J., Rochet, J. C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., Lansbury Jr., P. T., (2001) Biochemistry, 40, pp. 7812-7819
Kazlauskaite, J., Sanghera, N., Sylvester, I., Venien-Bryan, C., Pinheiro, T. J., (2003) Biochemistry, 42, pp. 3295-3304
Bokvist, M., Lindstrom, F., Watts, A., Grobner, G., (2004) J. Mol. Biol., 335, pp. 1039-1049
Gerke, V., Creutz, C. E., Moss, S. E., (2005) Nat. Rev. Mol. Cell Biol., 6, pp. 449-461
Rescher, U., Gerke, V., (2004) J. Cell Sci., 117, pp. 2631-2639
Seaton, B. A., (1996) Annexins: Molecular Structure to Cellular Function, , Seaton B. A. (Ed), R. G. Landes Co., Austin, TX
Fehmann, H. C., Weber, V., G ke, R., G ke, B., Arnold, R., (1990) FEBS Lett., 262, pp. 279-281
Rothman, J. E., Lenard, J., (1977) Science, 195, pp. 743-753
Parkash, J., Chaudry, M. A., Amer, A. S., Christakos, S., Rhoten, W. B., (2002) Endocrine, 18, pp. 221-230
Hanabusa, T., Kubo, K., Oki, C., Nakano, Y., Okai, K., Sanke, T., Nanjo, K., (1992) Diabetes Res. Clin. Pract., 15, pp. 89-96
Cooper, G.S.J., Willis, A.C., Clark, A., Turner, R.C., Sim, R.B., Reid, K.B.M., (1987) Proc. Natl. Acad. Sci. USA, 84, pp. 8628-963
Seaton, B.A., (1996) Annexins: Molecular Structure to Cellular Function, , Seaton B.A. (Ed), R. G. Landes Co., Austin, TX
Fehmann, H.C., Weber, V., Göke, R., Göke, B., Arnold, R., (1990) FEBS Lett., 262, pp. 279-281
Rothman, J.E., Lenard, J., (1977) Science, 195, pp. 743-753
DeFronzo, R.A., Bonadonna, R.C., Ferranini, E., Insulin resistance: A multifaceted syndrome responsible for NIDDM. obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease (1991) Diabetes Care, 14, pp. 173-17
Cahil, G.F., MacDevit, H.O., Insulin-dependent diabetes mellitus: The initial lesion (1981) N Engl J Med, 304, pp. 1454-1465
Marner, B., Agner, T., Binder, C., Increased reduction in fasting C-peptide is associated with islet cell antibodies in Type I (insulin dependent) diabetic patients (1985) Diabetologia, 28, pp. 8775-8880
Bougneres, P.F., Carel, J.C., Castano, L., Factors associated with early remission of Type I diabetes in children treated with cyclosporine (1988) N Engl J Med, 318, pp. 663-670
Boden, G., Role of fatty acids in the pathogenesis of insulin resistance in NIDDM (1997) Diabetes, 46, pp. 3-10
Bantle, J.P., Latine, D.C., Castle, G.W., Postprandial glucose and insulin responses to meals containing different carbohydrates in normal and diabetic subjects (1983) N Engl J Med, 309, pp. 7-12
Soman, V.R., Koivisto, V.A., Diebert, D., Increased insulin sensitivity and insulin binding to monocytes after physical training (1979) N Engl J Med, 301, pp. 1200-1204
Helmrich, S.P., Ragland, D.R., Leung, R.W., Paffenbarger, R.S., Physical activity and reduced occurrence of non-insulin dependent diabetes mellitus (1991) N Engl J Med, 325, pp. 147-152
Kramer, W., Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride (1994) Biochem Biophys Acta, 1191, pp. 278-290
Muller, G., Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor I. Binding characteristics (1994) Biochem Biophys Acta, 1191, pp. 267-277
Draeger, K.E., Clinical profile of glimepiride (1995) Diabetes Res Clin Pract, 28 (SUPPL.), pp. S139-S146
Müller, G., Satoh, Y., Geisen, K., Extrapancreatic effects of sulfonylureas - A comparison between glimepiride and conventional sulfonylureas (1995) Diabetes Res Clin Pract, 28 (SUPPL.), pp. S115-S137
Berger, M., Oral agents in the treatment of diabetes mellitus (1986) Clinical Diabetes Mellitus: A Problem Oriented Approach, p. 266. , Davidson JK (ed): New York, Thieme
(1997) Dicionário de Especialidades Farmacêuticas, 26a Edição
Bailey, C.J., Biguanides and NIDDM (1992) Diabetes Care, 15, pp. 755-772
Nolan, J.J., Ludvik, B., Beerdsen, P., Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. W (1994) Engl J Med, 331, pp. 1188-1193
Beck-Nielsen, H., Effects of GR92132, a thiazolidinedione in non-insulin-dependent diabetes (1994) Diabetologia, 37 (SUPPL.), pp. A209
Mimura, U., Hiramatsu, F., Effects of a new oral hypoglycaemic agent (CS 045) on metabolic abnormalities and insulin resistance in Type 2 diabetes (1994) Diabet Med, 11, pp. 685-691
Suter, S.L., Nolan, J.J., Wallace, P., Metabolic effects of new oral hyperglycaemic agent CS-045 in NIDDM subjects (1992) Diabetes Care, 15, pp. 193-203
Madar, Z., The effect of acarbose and miglitol (BAY-M-1099) on post-prandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats (1989) J Nutr, 119, pp. 2023-2029
Sailer, D., The influence of a new glucoside hydroxylase inhibitor on blood glucose and serum insulin concentration in non-insulin treated diabetes (1981) Horm Metab Res, 13, pp. 55-58
Hanefeld, M., Fisher, S., Schulze, J., Spengler, M., Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone (1991) Diabetes Care, 14, pp. 732-737
Reaven, G.M., Lardinois, C.K., Greenfield, M.S., Schwartz, H.C., Vreman, H.J., Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas (1990) Diabetes Care, 13 (3 SUPPL.), pp. 32-36
Chiasson, J.L., Josse, R.G., Hurt, J.A., Palmason, C., The eddicacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus (1994) Ann Intern Med, 121 (12), pp. 928-935
Bojestig, M., Arnqvist, H.J., Hermansson, G., Declining incidence of nephropathy in insulindependent diabetes mellitus (1983) N Engl J Med, 330, pp. 15-18
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus (1993) N Engl J Med, 329, pp. 977-986
Reichard, P., Nillson, B.Y., Rosenqvist U the effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus (1993) N Engl J Med, 329, pp. 304-309
Pampanelli, S., Torlone, E., Lalli, C., DelSindaco, P., Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function (1995) Diabetes Care, 18, pp. 1452-1459
Howey, D.C., Bowsher, R.R., Brunelle, R.J., Woodworth, J.R., {Lys(B28), Pro(B29)} human insulin: A rapidly absorved analog of human insulin (1994) Diabetes, 43, pp. 396-402
Gardner, D.F., Araki, R.F., Podet, E.J., Nell, L.J., Thomas, J.W., Field, J.B., The pharmacokinetics of subcutaneous regular insulin in type I diabetes patients: Assessment using a glucose clamptechnique (1986) J Clin Endocrinol Metab, 63, pp. 689-694
Lendrum, R., Walter, G., Gamble, D.R., Islet-cell antibodies in juvenile diabetes mellitus of recent onset (1975) Lancet, 1, pp. 880-885
Zinman, B., The physiologic replacement of insulin: An elusive goal (1989) N Engl J Med, 321, pp. 363-370
Paul Robertson, R., Pancreatic and islet transplantation for diabetes - Cures or curiosities? (1992) N Engl J Med, 327, pp. 1861-1868
National Diabetes Data Group Classification and Diagnosis of diabetes mellitus and other categories of glucose intolerance (1979) Diabetes, 28, pp. 1039-105
Calil, G.F., Macdevit, H.O., Insulin-dependent diabetes mellitus: The inicial lesion (1981) N Engl J Med, 304, pp. 1454-1465
Alberti, K.G.M.M., Zimmet, P.Z., Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications (1998) Diabetic Medicine, 15, pp. 539-553
Gerich, J.E., Oral hypoglicemic agents (1989) N Engl J Med, 321, pp. 1232-1245
Stumvall, M., Nurjhan, N., Perriello, G., Dailey, G., Gerich, J., Metabolic effects of metformin in non insulin- dependent diabetes mellitus (1995) N Engl J Med, 333, pp. 550-554
White Jr., R.J., The Pharmacological reduction of blood glucose in patients with type 2 diabetes mellitus (1998) Clin Diabetes, 16 (2)
Lebovitz, H., A new oral therapy for diabetes management: Alpha-glucosidase inhibition with acarbose (1995) Clin Diabetes, 13, pp. 99-102
Conif, R.F., Shapiro, J.A., Seaton, T.B., Bray, G., Multicenter placebo controlled trial comparing acarbose with placebo, tolbutamide, and tolbutamide-plus-acarbose in non insulin-dependent diabetes mellitus (1995) Am J Med, 98, pp. 443-451
Santeusanio, F., Compagnucci, P., A risk-benefit appraisal of acarbose in the management of non insulin-dependent diabetes mellitus (1994) Drug Safety, 11, pp. 432-444
Hanefeld, M., Fischer, S., Schulze, J., Spengler, M., Wargenau, M., Schollberg, K., Fucker, K., Therapeutic potentials of acarbose as a first-line drug in NIDDM insufficiently treated with diet alone (1991) Diabetes Care, 14, pp. 732-737
Foot, E.A., Lettis, S., (1997) A Novel Anti Diabetic Agent. 16 th IDFC
Salzman A, Collegeville PA. USA. The European Association for the Study of Diabetes. Brussels, outubro de 1999Grumberg G, Weston M. W. Collegeville, PA, USA. The European Association for the Study of Diabetes. Brussels, outubro de 1999Balfour, A.J., Faulds, D., Repaglinide (1998) Drugs Aging, 13, pp. 173-180
Lindholm, A., Mcewen, J., Anders, P., Improved postprandial glycemic control with insulin Aspart (1999) Diabetes Care, 22, pp. 801-805
Home, P., Lindholm, A., Hylleberg, B., Improved prandial glycemic control with insulin Aspart (1998) Diabetes Care, 21, pp. 1904-1909
Rosenstock, J., (1999) Efficacy and Safety of HOE 901 (Insulin Glargine) in Subjects with Type 2 Diabetes Mellitus, , The European Association for the Study of Diabetes. Brussels, outubro de
Jarvinen-Yki, H., Ryysy, L., Comparison of bedtime insulin regimens in patients with type 2 Diabetes Mellitus (1999) Ann Intern Med, 130, pp. 389-396
Decode (1999) The Lancet, 354, pp. 617-621
Jenny, G., (2000) Diabetes Care, 23, p. 1197
Manisha, C., Abhymanyu, G., Benefical effects of high dietary fiber intake in patients with type 2 diabetes mellitus (2000) N Engl J Med, 342, pp. 1392-1397
White R.J., Jr., The Pharmacological reduction of blood glucose in patients with type 2 diabetes mellitus (1998) Clin Diabetes, 16 (2)
Foot, E.A., Lattis, S., (1997) A Novel Anti Diabetic Agent. 16 th IDFC
Al-Salman, J., Arjomand, H., Kemp, D.G., Mittal, M., Hepatocellular injury in a patient receiving rosiglitazone (2000) Ann Intern Med, 132, pp. 121-124
Forman, Hepatic failure in a patient taking rosiglitazone (2000) Ann Intern Med, 132, pp. 118-121
Balfour, J.A.B., Plosker, G., Rosiglitazone (1999) Drugs, 57, pp. 921-930
Wolffenbuttel, B.H., Gomis, R., Squatrito, S., Addition of low dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients (2000) Diabet Med, 17, pp. 40-47
Fonseca, V., Rosenstock, J., Patwardhan, R., Salzman, A., Effect of metformin and rosiglitazone combination therapy patients with type 2 diabetes mellitus: A randomized control trial (2000) Jama, 283, pp. 1695-1702
(1999) Physician Desk Reference, pp. 3088-3092
Damsbo, P., Clauson, P., Marbury, T.C., Winfeld, K., A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients (1999) Diabetes Care, 22, pp. 789-794
Moses, R., Slobodniuk, R., Boyages, S., Additional treatment with repaglinide provides significant improvement in glycemic control in NIDDM patients poorly controlled on metformin (1997) 57 th Scientific Sessions of the American Diabetes Association, , Boston, MA, USA
Hanefeld, M., Bouter, K.P., Dickinson, S., Guitard, C., Rapid and short-acting mealtirre insulin secretion with nateglinide controls both prandial and mean glycemia (2000) Diabetes Care, 23, pp. 202-207
Walter, Y.H., Spratt, D.I., Garreffa, S., McLeod, J.F., Mealtime glucose regulation by nateglinide in type 2 diabetes mellitus (2000) Eur J Clin Pharmacol, 56, pp. 129-133
Hirschberg, Y., Karara, A.H., Pietri, H.O., McLeod, J.F., Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin (2000) Diabetes Care, 23, pp. 349-353
Choudhury, S., Hirschberg, Y., Filipek, R., Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis (2000) J Clin Pharmacol, 40, pp. 634-640
Zhou, H., Walter, Y.H., Smith, H., Devineni, D., McLeod, J.F., Nateglinide, a new mealtime glucose regulator (2000) Clin Drug Invest, 19, pp. 465-471
Roach, P., Yue, L., Arora, V., Improved postprandial glycemic control during treatment with Humalog Mix 25, a novel protamine-based insulin lispro formulation (1999) Diabetes Care, 22, pp. 1258-1261
Grumberg, G., Weston, M.W., (1999), Collegeville, PA, USA. The European Association for the Study of Diabetes. Brussels, outubro deRosenstock, J., (1999) Efficacy and Safety of HOE 901 (Insulin Glargine) in Subjects with Type 2 Diabetes Mellitus, , The European Association for the Study of Diabetes. Brussels, outubro de